[A19-30] Pembrolizumab (non-squamous non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 01.07.2019
Commission awarded on 29.03.2019 by the Federal Joint Committee (G-BA).
First-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC) in adults whose tumours have no EGFR or ALK positive mutations
Added benefit not proven for either of both research questions (PD-L1 expression < or ≥ 50%)
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.